Evidence map›Paper›PMID 36539683›Full record

ArticleBiological procedures online2022

Clinical Prognostic Factors and Integrated Multi-Omics Studies Identify Potential Novel Therapeutic Targets for Pediatric Desmoid Tumor.

Bo Ning, Peng Huang, Lining Zhu, Zhijie Ma, Xiaoli Chen, Haojun Xu, Ruixue Ma, Chengyun Yao, Pengfei Zheng, Tian Xia and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological procedures online, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bo Ning *Department of Paediatric Orthopedics, Children's Hospital of Fudan University, Shanghai, 201102, China.
Peng Huang *Department of Paediatric Orthopedics, Children's Hospital of Fudan University, Shanghai, 201102, China.
Lining Zhu *Department of Paediatric Orthopedics, Hainan Women and Children's Medical Center, Haikou, 570206, China.
Zhijie Ma *Department of Pathology, Nanjing Drum Tower Hospital & Drum Tower Clinical College & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.
Xiaoli ChenSir Run Run Hospital, Nanjing Medical University, Nanjing, 211166, China.
Haojun XuDepartment of Pathology, Nanjing Drum Tower Hospital & Drum Tower Clinical College & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China.
Ruixue MaDepartment of Paediatric Orthopedics, Children's Hospital of Fudan University, Shanghai, 201102, China.
Chengyun YaoJiangsu Cancer Hospital & The Affiliated Cancer Hospital of Nanjing Medical University& Jiangsu Institute of Cancer Research, Nanjing, 2100092, China. yaochengyun@jszlyy.com.cn.
Pengfei ZhengDepartment of Orthopedics Surgery, Children's Hospital of Nanjing Medical University, Nanjing, 210008, China. zhengpengfei@njmu.edu.cn.
Tian XiaDepartment of Paediatric Orthopedics, Children's Hospital of Fudan University, Shanghai, 201102, China. xiatian@fudan.edu.cn.
Hongping XiaDepartment of Pathology, Nanjing Drum Tower Hospital & Drum Tower Clinical College & Key Laboratory of Antibody Technique of National Health Commission, Nanjing Medical University, Nanjing, 211166, China. xiahongping@njmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDesmoid tumor (DT), also known as desmoid-type fibromatosis (DTF) or aggressive fibromatosis (AF) is a rare mesenchymal tumor affecting both children and adults. It is non-metastasis but infiltrative, growing with a high recurrence rate to even cause serious health problems. This study investigates the biology of desmoid tumors through integrated multi-omics studies.

methodsWe systematically investigated the clinical data of 98 extra-abdominal cases in our pediatric institute and identified some critical clinical prognostic factors. Moreover, our integrated multi-omics studies (Whole Exome Sequencing, RNA sequencing, and untargeted metabolomics profiling) in the paired PDT tumor/matched normal tissues identified more novel mutations, and potential prognostic markers and therapeutic targets for PDTs.

resultsThe top mutation genes, such as CTNNB1 (p.T41A and p.S45F) and MUC4 (p.T3775T, p.S3450S, etc.), were observed with a mutation in more than 40% of PDT patients. We also identified a panel of genes that are classed as the FDA-approved drug targets or Wnt/β-catenin signaling pathway-related genes. The integrated analysis identified pathways and key genes/metabolites that may be important for developing potential treatment of PDTs. We also successfully established six primary PDT cell lines for future studies.

conclusionsThese studies may promote the development of novel drugs and therapeutic strategies for PDTs.

Indexed as

Clinical prognostic factorsPediatric desmoid tumorRNA sequencingUntargeted metabolomics profilingWhole exome sequencing

Identifiers

PMID36539683
PMCPMC9768966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.